Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group.

Precision medicine is a dynamic area embracing a diverse and increasing type of approaches that allow the targeting of new medicines, screening programs or preventive healthcare strategies, which include the use of biologic markers or complex tests driven by algorithms also potentially taking account of patient preferences. The International Society for Pharmacoeconomics and Outcome Research expanded its current work around precision medicine to (1) describe the evolving paradigm of precision medicine with examples of current and evolving applications, (2) describe key stakeholders perspectives on the value of precision medicine in their respective domains, and (3) define the core factors that should be considered in a value assessment framework for precision medicine. With the ultimate goal of improving health of well-defined patient groups, precision medicine will affect all stakeholders in the healthcare system at multiple levels spanning the individual perspective to the societal perspective. For an efficient, timely and practical precision medicine value assessment framework, it will be important to address these multiple perspectives through building consensus among the stakeholders for robust procedures and measures of value aspects, including performance of precision mechanism; aligned reimbursement processes of precision mechanism and subsequent treatment; transparent expectations for evidence requirements and study designs adequately matched to the intended use of the precision mechanism and to the smaller target patient populations; recognizing the potential range of value-generation such as ruling-in and ruling-out decisions.

[1]  Katherine Payne,et al.  Economic evaluations of personalized medicine: existing challenges and current developments , 2015, Pharmacogenomics and personalized medicine.

[2]  S. Ou,et al.  Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? , 2014, Front. Oncol..

[3]  Sean Khozin,et al.  Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study. , 2018, Health affairs.

[4]  Rae Woong Park,et al.  Characterizing treatment pathways at scale using the OHDSI network , 2016, Proceedings of the National Academy of Sciences.

[5]  A. Holtorf,et al.  Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs , 2019, Front. Med..

[6]  W. Rogowski,et al.  What is personalized medicine: sharpening a vague term based on a systematic literature review , 2013, BMC Medical Ethics.

[7]  Mark Nuijten,et al.  Stratified Medicine and Reimbursement Issues , 2012, Front. Pharmacol..

[8]  Katherine Payne,et al.  Fish and chips all round? Regulation of DNA-based genetic diagnostics. , 2009, Health economics.

[9]  K. Payne,et al.  Current methodological issues in the economic assessment of personalized medicine. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  M. Ringo,et al.  Are Global Health Systems Ready for Transformative Therapies? , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  Katherine Payne,et al.  Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  M. Piccart,et al.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  T. Lieu,et al.  Evaluating Frameworks That Provide Value Measures for Health Care Interventions. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  Scott D Ramsey,et al.  Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  S. Daack-Hirsch,et al.  The role of patient engagement in personalized healthcare. , 2014, Personalized medicine.

[16]  Uwe Siebert,et al.  Personalized medicine in Europe: not yet personal enough? , 2017, BMC Health Services Research.

[17]  Adam P Dicker,et al.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Clarke,et al.  Communication of Information about Genetic Risks: Putting Families at the Center. , 2018, Family process.

[19]  Estela S Estape,et al.  Translation in Data Mining to Advance Personalized Medicine for Health Equity. , 2016, Intelligent information management.

[20]  A. Barratt,et al.  Evidence Based Medicine and Shared Decision Making: the challenge of getting both evidence and preferences into health care. , 2008, Patient education and counseling.

[21]  Mark R. Trusheim,et al.  Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.

[22]  Louis P Garrison,et al.  An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  Yusuke Nakamura,et al.  Pharmacogenomics and Patient Care: One Size Does Not Fit All , 2012, Science Translational Medicine.

[24]  S. Astley,et al.  Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  V. Zah,et al.  Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  Mark Kroese,et al.  'Personalized medicine': what's in a name? , 2014, Personalized medicine.

[27]  B. Knoppers,et al.  Personalized medicine and access to health care: potential for inequitable access? , 2012, European Journal of Human Genetics.

[28]  M. Ignatiadis,et al.  Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine. , 2019, Cancer research.

[29]  Louis P Garrison,et al.  Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  Oguzhan Alagoz,et al.  Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation , 2014, PharmacoEconomics.

[31]  I. Budin-Ljøsne,et al.  Patient and interest organizations’ views on personalized medicine: a qualitative study , 2016, BMC Medical Ethics.

[32]  A. Butte,et al.  Disease Risk Factors Identified Through Shared Genetic Architecture and Electronic Medical Records , 2014, Science Translational Medicine.

[33]  Deirdre Mladsi,et al.  The faces of personalized medicine: a framework for understanding its meaning and scope. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  Martin Eden,et al.  Toward health technology assessment of whole-genome sequencing diagnostic tests: challenges and solutions. , 2017, Personalized medicine.

[35]  Bertalan Meskó,et al.  The role of artificial intelligence in precision medicine , 2017 .

[36]  A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics , 2016, Front. Genet..

[37]  Randy Burkholder,et al.  ISPOR's Initiative on US Value Assessment Frameworks: An Industry Perspective. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[38]  Hannah Wood,et al.  The Future of Precision Medicine: Potential Impacts for Health Technology Assessment , 2018, PharmacoEconomics.

[39]  P. Neumann,et al.  Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[40]  P. Williams-Russo,et al.  The case for more active policy attention to health promotion. , 2002, Health affairs.

[41]  Hendrik Koffijberg,et al.  A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models , 2017, Expert review of pharmacoeconomics & outcomes research.

[42]  C. Marzuillo,et al.  How is genetic testing evaluated? A systematic review of the literature , 2018, European Journal of Human Genetics.

[43]  Robert M. Plenge,et al.  Disciplined approach to drug discovery and early development , 2016, Science Translational Medicine.

[44]  K. Facey,et al.  Putting Patients at the Centre of Healthcare: Progress and Challenges for Health Technology Assessments , 2018, The Patient - Patient-Centered Outcomes Research.

[45]  Y. Vergouwe,et al.  Validation, updating and impact of clinical prediction rules: a review. , 2008, Journal of clinical epidemiology.

[46]  P. Froguel,et al.  Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science? , 2015, Therapie.

[47]  Josh J. Carlson,et al.  The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis , 2013, Breast Cancer Research and Treatment.

[48]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[49]  E. Pearson Personalized medicine in diabetes: the role of ‘omics’ and biomarkers , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[50]  B. Larijani,et al.  Ethical Issues Surrounding Personalized Medicine: A Literature Review. , 2017, Acta medica Iranica.

[51]  Maarten J. IJzerman,et al.  Health economic impact of liquid biopsies in cancer management , 2018, Expert review of pharmacoeconomics & outcomes research.

[52]  B. Knoppers,et al.  The ethical framing of personalized medicine , 2014, Current opinion in allergy and clinical immunology.

[53]  K. Payne,et al.  Identification of factors that may influence the selection of first‐line biological therapy for people with psoriasis: a prospective, multicentre cohort study , 2017, The British journal of dermatology.

[54]  D. Mott Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind? , 2018, The Patient - Patient-Centered Outcomes Research.

[55]  R. Green,et al.  Assessing the Costs and Cost-Effectiveness of Genomic Sequencing , 2015, Journal of personalized medicine.

[56]  K. Kinzler,et al.  Applications of liquid biopsies for cancer , 2019, Science Translational Medicine.

[57]  Yann Joly,et al.  Integrating precision cancer medicine into healthcare—policy, practice, and research challenges , 2016, Genome Medicine.